A Bluetooth-enabled smart add-on device for insulin pen injectors, BIOCORP ’s Mallya is designed to gather the dose and time of individual injection and send the real-time data to a companion software.
The device could aid diabetes patients in maintaining a consistent dose log, BIOCORP noted.
Novo Nordisk provides most of its insulins with the FlexTouch pen, which is also part of its launch plan for all new insulins.
Under the latest partnership, a specific Mallya version will be created for the insulin delivery pen.
FlexTouch is said to be the first prefilled insulin delivery device without push-button extension.
Based on the pen’s dosing mechanism, the push button does not extend at any dose and enables insulin administration by pressing the low injection force button.
BIOCORP added that the current Mallya device needs to be redesigned to cater to this mechanism while retaining its accuracy and reliability for the user.
The new Mallya will be connected directly to the disposable pre-filled FlexTouch pen and enable efficient dose logging for patients and their healthcare providers, which could lead to more individualised treatments.
Novo Nordisk digital health vice-president Søren Smed Østergaard said: “This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes.”
As part of the agreement, BIOCORP is eligible for an upfront payment as well as various milestone payments.
Earlier this month, Biocorp signed a partnership deal with Merck to develop and market a specific version of the Mallya device for use in the field of Human Growth Hormone (HGH).